Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:

NCT ID: NCT06038253 Not yet recruiting - Osteoporosis Clinical Trials

Relation Between NAFLD and BM DENSITY

Start date: October 1, 2023
Phase:
Study type: Observational

In general NAFLD is a common denominal for a broad spectrum of damage to the liver, which can be due to hepatocyte injury, inflammatory processes and fibrosis. This is normally seen on liver biopsy and can range from milder forms (steatosis) to the more severe forms (non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis and liver failure). In these patients, advanced fibrosis is the major predictor of morbidity and liver-related mortality, and an accurate diagnosis of NASH and NAFLD is mandatory . NAFLD is closely associated with metabolic disorders, including central obesity, dyslipidaemia, hypertension, hyperglycaemia and persistent abnormalities of liver function tests. NAFLD was shown to be connected with diseases that are usually not dependent on obesity, such as sarcopenia and osteoporosis Target of the study : 1. Clarify predictive value of fibroscan and u/s in diagnosis of NAFLD. 2. Estimate the metabolic effect of NAFLD on bone density 3. Estimate the correlation between obesity , NAFLD and BMD

NCT ID: NCT06024148 Not yet recruiting - Clinical trials for Osteoporosis Fracture

Continuation of Anti-osteoporotic Treatment 1 Year After Initial Administration

POUROSTEO
Start date: September 2023
Phase:
Study type: Observational

The aim of this observational study is to assess the obstacles and levers to the continuation of anti-osteoporotic treatment, and to identify those where action could be taken to improve the quality of care for fractured patients. The individual and collective stakes are high. Fracture is the most feared complication of osteoporosis. The current under-diagnosis and under-treatment of this chronic pathology exposes patients to a high risk of early re-fracture, with the associated morbidity and mortality. General practitioners have a major role to play in monitoring and coordinating patients' healthcare pathways. The aim of this study is to assess ways of improving osteoporosis management in order to improve quality of life and disability-free life expectancy for individual patients. The public health and economic stakes are equally high. It is by identifying the obstacles that prospective work on the key elements to be implemented could help optimize osteoporosis management.

NCT ID: NCT05998863 Not yet recruiting - Osteoporosis Clinical Trials

Effervescent Calcium Magnesium Citrate to Prevent Mineral Metabolism and Renal Complications of Chronic Proton Pump Inhibitor Therapy

Start date: March 15, 2024
Phase: Phase 3
Study type: Interventional

Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteoporosis), hypomagnesemia (magnesium deficiency) and increased risk of chronic kidney disease (CKD). The current trial represents the investigators ongoing effort to discern whether these complications could be averted by effervescent calcium magnesium citrate (EffCaMgCit).

NCT ID: NCT05946278 Not yet recruiting - Clinical trials for Age-Related Osteoporosis

Genetic Regulators of Bone Health That Are Unique to Vertebral Bone

Start date: February 2024
Phase:
Study type: Observational

Osteoporosis is an age related disease in which a person's bone slowly becomes weaker with time. The bones may become so weak that they break easily such as a fall from standing height. The most commonly broke bones in osteoporosis are those of the hip, the spine or the wrist. Osteoporosis runs in families meaning that genetic differences explain why some people break bones in old age and other do not. Genetic studies have been done that show the the genes associated with spine (vertebral) fractures (broken bones) and hip fractures are different, suggesting that osteoporosis of the spine is not the exact same disease as osteoporosis of the hip. Genetic studies tell us what part of the genome (i.e. genes) are associated with a disease, but do not tell us how these genes act biologically to cause that disease. In this study, we seek to determine how the genes uniquely associated with spine osteoporosis behave in normal and aged bone, to determine how they interact with each other as a team to impact spine bone. In this study, we will measure gene activity (so called gene expression) in bone samples taken from people undergoing major spine deformity surgery. We will using genetic data from these patients to determine how gene activity is controlled in bone and how that relates to measures of bone health such as bone mineral density data. The results of this study will provide critical data regarding how osteoporosis of the spine happens, and these data will be used to find better and safer treatments to prevent bone fractures of the spine that happen with age.

NCT ID: NCT05943600 Not yet recruiting - Osteoporosis Clinical Trials

An Assessment of Treatment Adherence of Osteoporosis Patients From a Biopsychosocial Perspective

Start date: July 15, 2023
Phase:
Study type: Observational

This observational study aims to learn about the psychosocial risk factors of osteoporosis (OP) patients. The main question it aims to answer is: - Which biopsychosocial factors affect OP patients' fragility fracture risk regarding the health behaviour model? Participants will fulfil these forms below here; - Sociodemographic and Clinical Information Form, - Fragility Fracture Information Form - Medication Adherence Report Scale - Brief Illness Perception Scale - The Beliefs About the Medicines Scale-Specific - The Short Assessment of Patient Satisfaction - Perceived Stress Scale - Multidimensional Perceived Social Support Scale - Brief Symptom Inventory - Depression and Anxiety - Health Behavior Assessment Scale

NCT ID: NCT05937945 Not yet recruiting - Osteoporosis Clinical Trials

Studying Patient Experiences in Osteoporosis Clinical Trials

Start date: July 2024
Phase:
Study type: Observational

Clinical trials for osteoporosis are designed to assess the safety and effectiveness of novel osteoporosis treatments. These trials play a crucial role in establishing whether these new treatments outperform existing options and provide substantial evidence to support their adoption within the wider population. The primary aim of this particular study is to investigate the experiences of individuals diagnosed with osteoporosis who participate in a distinct clinical trial involving a medical intervention. The focus will be on closely monitoring the rates of trial completion and withdrawal among these participants.

NCT ID: NCT05923736 Not yet recruiting - Osteoporosis Clinical Trials

Cardiovascular Risk in Digital Osteoarthritis

RICARDI
Start date: February 4, 2024
Phase: N/A
Study type: Interventional

The goal of this cross-sectional case control study is to investigate the cardiovascular risk in digital osteoarthritis. This study aims to compare the cardiovascular risk between group of patients with digital osteoarthritis and control group of patients with non-osteoarthritis disease paired by measurement of carotid intima-media thickness. All participants will undergo an ultrasound scan to measure carotid intima media thickness, a clinical assessment with the rheumatologist and a cardiovascular risk assessment.

NCT ID: NCT05911477 Not yet recruiting - Osteoporosis Clinical Trials

Recombinant Human Bone Morphogenetic Protein-2(rhBMP-2) in Patients With Osteoporosis After Lumbar Fusion

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

rhBMP-2 has been used to promote spinal fusion. Despite potential risk of complications, satisfied results could be obtained with low dose of rhBMP-2. Effect of early bone formation has been validated using rat ovariectomy osteoporosis model. However, whether it functioned in patients with osteoporosis remained unknown. In this study, the investigators intend to investigate whether rhBMP-2 promotes early bone formation in patients with osteoporosis after transforaminal lumbar interbody fusion (TLIF).

NCT ID: NCT05902078 Not yet recruiting - Clinical trials for Postmenopausal Osteoporosis

Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis

EFFECT
Start date: June 2023
Phase: Phase 4
Study type: Interventional

To investigate the efficacy and safety of eldecalcitol in postmenopausal women with low bone mineral density (BMD) or mild osteoporosis through a randomized, open-label, parallel controlled trial with calcitriol as the control.

NCT ID: NCT05851131 Not yet recruiting - Osteoporosis Clinical Trials

Surveying Knowledge, Attitudes, and Practices of Primary Care Physicians in Turkey Regarding Osteoporosis Management.

Start date: August 1, 2023
Phase:
Study type: Observational

This study aims to assess the knowledge of primary care physicians on the diagnosis and treatment of osteoporosis.